Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (SWB:I76)
This article provides an overview of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76) including its financial actuals, analyst estimates, and key financial metrics. It covers information on stock performance, future earnings forecasts, past revenue, net income, and employee count. The article also clarifies that Ironwood Pharmaceuticals does not pay dividends and offers instructions on how to purchase its stocks.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (BX:I76)
This article provides financial actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (BX:I76), covering income statements, balance sheets, and cash flow data. It includes analyst forecasts, earnings reports, revenue figures, and other financial metrics. The company's stock ticker, next earnings date (August 6, 2026), and recent financial performance are detailed.
I76 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Ironwood Pharmaceuticals, Inc. Class A (I76), including analyst price targets and predictions for 2027. It details earnings, revenue, and net income figures, and answers frequently asked questions about the company's stock, historical prices, and financial reporting.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (MUN:I76)
This article provides actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (MUN:I76), covering financial data, analyst forecasts, and company details. It includes information on earnings, revenue, net income, and dividend policy, as well as an overview of its stock performance history. The article also addresses frequently asked questions about the company's financials and stock trading.
Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares
Ironwood Pharmaceuticals director Catherine Moukheibir has received an equity award of 63,481 shares of Class A common stock, granted as restricted stock with no cash cost. These shares will vest in full on the day before the next annual stockholders' meeting, requiring her continued service. Following this grant, Moukheibir directly holds a total of 181,425 shares of Ironwood Class A common stock.
Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan
Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where directors were also elected and other proposals received strong support. The amendment expands the pool for employee, officer, and director incentives, as detailed in the company's 8-K filing.
Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant
Ironwood Pharmaceuticals director Jay Shepard has been granted 63,481 restricted Class A common shares as equity compensation, with no cash cost. The grant was made under the company's Second Amended and Restated Non-employee Director Compensation Policy and vests in full before the next calendar year's annual stockholders' meeting. Following this award, Shepard directly holds 235,036 shares of Ironwood Class A common stock.
Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting
Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy and will vest in full on the date immediately preceding the next annual meeting of stockholders. Following these awards, Denner's direct holdings increased to 323,855 shares.
Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4
Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, increasing his direct holdings to 253,820 shares. This transaction is a routine director equity award rather than an open-market purchase or sale.
Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant
Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company’s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this grant, Kessler now directly holds 229,364 shares of Class A Common Stock.
Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant
Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these transactions, McHugh directly holds 272,320 shares.
Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant
Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricted stock is set to vest in full on the date immediately preceding the next year's annual meeting of stockholders.
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead
Ironwood Pharmaceuticals, Inc. (IRWD) anticipates a strong year with projected net sales growth and debt reduction. The company expects continued strong performance from LINZESS and the advancement of Apraglutide into a new confirmatory trial, positioning it for potential class leadership due to its favorable clinical profile. This outlook was based on insights from the Jefferies Global Healthcare Conference 2026.
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant
Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19, 2026, which will vest over two years. This compensation structure aims to align his pay with the company's share performance during his interim role.
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant
Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following this transaction, Silver directly holds a total of 441,570 shares of the company's common stock, demonstrating a significant equity stake.
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week® 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and tolerability data for apraglutide, an investigational drug for SBS, and linaclotide data for other gastrointestinal conditions like IBS-C, CIC, and functional constipation. These presentations aim to deepen the understanding of current management and inform future therapeutic approaches for these challenging conditions.
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares, and exercises shared voting and dispositive power. The Master Fund explicitly disclaims beneficial ownership through its Investment Management Agreement, as it lacks the ability to vote or dispose of these securities.
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD
This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agreements, and quarterly earnings reports. The news also highlights broader biotech sector developments that impact IRWD.
Renaissance reports 4.90% stake in Ironwood (IRWD)
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power. The disclosure was made via an Amendment No. 1 to a Schedule 13G/A SEC filing.
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD)
This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial guidance, and developments in treatments for short bowel syndrome.
[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event
Ironwood Pharmaceuticals (IRWD) announced that its Senior Vice President and Chief Financial Officer, Gregory Martini, will resign effective May 15, 2026. The company stated this resignation is unrelated to any disagreement concerning its financial reporting. Ronald Silver, currently Senior Vice President, Corporate Controller, and Chief Accounting Officer, will assume the role of interim chief financial officer and principal financial officer on the same date, ensuring continuity in financial leadership.
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Ironwood Pharmaceuticals (NASDAQ:IRWD) significantly beat revenue and earnings per share expectations in its latest quarterly report, leading to new forecasts from analysts. While analysts maintained similar revenue and EPS estimates for 2026, the price target for the stock rose by 26% to US$6.10, indicating increased confidence in the business's intrinsic value. The company is also expected to outpace industry growth, with revenues projected to increase 38% annually until the end of 2026.
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) News, Articles, Events & Latest Updates
This article provides news and updates for Ironwood Pharmaceuticals Inc (IRWD), including recent financial performance and upcoming events. Despite beating Q1 earnings and revenue estimates driven by strong LINZESS sales, the stock experienced a slight dip. The company continues to focus on developing and commercializing therapies for gastrointestinal and rare diseases.
Ironwood Pharmaceuticals (IRWD) Q1 Profit Of US$40.8 Million Tests Bearish Earnings-Decline Narrative
Ironwood Pharmaceuticals (IRWD) reported a Q1 profit of US$40.8 million, challenging a bearish earnings-decline narrative with US$106.5 million in revenue and US$0.25 basic EPS. While bulls point to a profitable trailing twelve-month profile, bears highlight fluctuating quarterly net income, future revenue declines, and concerns about heavy reliance on key products. The company's stock trades at a low P/E compared to peers, with a high debt and negative equity balance sheet which presents a mixed signal for investors.
Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge
Ironwood Pharmaceuticals (IRWD) reported a significant financial turnaround in Q1 2026, swinging from a net loss to a profit, primarily driven by a substantial increase in LINZESS revenue. Total revenues surged to $106.5 million from $41.1 million year-over-year, leading to a diluted EPS of $0.24 compared to a loss of $0.23 in the prior year. The company's focus on its GI franchise and advancing apraglutide through clinical development contributed to improved operating income despite ongoing debt obligations.
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04
This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 28.97%, bringing it to $7.04. The content provided is minimal, offering only this specific financial update without further details or analysis.
Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy
Ironwood Pharmaceuticals is proposing an amendment to its Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 shares for equity awards, seeking stockholder approval at its 2026 annual meeting on June 16, 2026. The company emphasizes the necessity of this increase to attract, retain, and incentivize key talent, aligning executive compensation with long-term stockholder value. Stockholders will also vote on the election of eight directors, an advisory say-on-pay for executive compensation, and the ratification of KPMG LLP as the 2026 auditors.
Book value per share of Ironwood Pharmaceuticals, Inc. Class A – SWB:I76
The article focuses on the book value per share of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76), traded on the Stuttgart Stock Exchange. It provides financial data and a general overview of the company's financials for various periods, without delving into specific numbers in the provided text. The content is presented within the context of TradingView, a platform for market data and analysis.
Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals
Bank of America Corporation has disclosed a 6.1% beneficial ownership stake in Ironwood Pharmaceuticals (NASDAQ: IRWD), totaling 9,962,355 Class A Common Stock shares. This information comes from a Schedule 13G/A filing, referencing 163,058,316 outstanding shares as of January 31, 2026. The filing indicates a shared voting and dispositive power over these shares by Bank of America and its subsidiaries.
The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment
The Vanguard Group filed an amendment to its Schedule 13G/A report, declaring zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing clarifies that Vanguard itself no longer reports beneficial ownership of these subsidiary holdings.
Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%
Sarissa Capital Management LP and Alexander J. Denner have reduced their stake in Ironwood Pharmaceuticals (IRWD) through the sale of 6.7 million shares on March 17, 2026, for over $20.5 million. Despite the significant sale, Sarissa Capital still beneficially owns 5.6% of Ironwood's outstanding shares, while Alexander J. Denner holds approximately 5.8%, including shares received as director compensation. The transactions were reported in an amended Schedule 13D filing, indicating a notable reduction in position size by an active holder while maintaining a substantial stake.
Ironwood Pharmaceuticals director Denner sells $20.5m in shares
Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued, and analysts like Jefferies and Citizens have raised their price targets for IRWD following the company's Q4 2025 earnings report and reaffirmed 2026 guidance. The company also confirmed it met the liquidity conditions for its Credit Agreement.
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com
Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility but a significant yearly gain. Despite the insider sale, InvestingPro analysis indicates the stock is undervalued, and several analysts have recently raised price targets for the company, citing strong Linzess sales and reaffirmed 2026 guidance. Ironwood also reported meeting liquidity conditions under its Credit Agreement.
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale
Investment vehicles advised by Sarissa Capital Management LP, associated with director Alexander J. Denner, sold off 6.7 million shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A Common Stock on March 17, 2026, at prices between $3.05 and $3.31 per share. This major sale significantly reduced their indirect holdings, though they still retain over 9 million shares. Separately, Dr. Denner received a smaller equity grant of 4,451 shares, bringing his direct holdings to 256,309.
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant
Ironwood Pharmaceuticals (IRWD) CFO Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. This award is in the form of restricted stock units, vesting in four equal installments over approximate anniversaries of the grant date. Following this transaction, Martini directly holds 297,213 shares of Class A Common Stock, as detailed in the SEC Form 4 filing.
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Chief Commercial Officer Tammi L. Gaskins was granted 136,612 restricted shares of Class A Common Stock as an equity award. This compensation award vests in four equal annual installments, tying the value to continued service and performance. Following this grant, Ms. Gaskins' direct holdings increased to 350,350 shares.
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award
Ironwood Pharmaceuticals (NASDAQ: IRWD) CEO Thomas A. McCourt was granted a restricted stock unit award of 409,836 shares of Class A Common Stock. This annual performance award, valued at $0 per share, vests in three equal installments on each approximate anniversary of the grant. Following this transaction, McCourt directly holds 1,898,838 shares of Class A Common Stock.
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant
John Minardo, the Chief Legal Officer of Ironwood Pharmaceuticals (IRWD), was granted 136,612 shares of Class A Common Stock as a restricted stock unit award. This award, part of his annual performance compensation, vests in four equal installments annually. Following this grant, Minardo directly holds a total of 500,498 shares of the company's Class A Common Stock.
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award
Ironwood Pharmaceuticals' principal accounting officer, Ronald Silver, received a grant of 163,934 restricted stock units (RSUs) as part of a stock-based compensation award. This grant, with a value of $0 per share, vests in four equal annual installments and increases his direct holdings to 416,570 shares. The transaction was reported in an SEC Form 4 filing, indicating it was a compensation award rather than an open-market purchase.
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant
Michael Shetzline, Senior Vice President and Chief Medical Officer at Ironwood Pharmaceuticals (IRWD), has been granted 136,612 shares of Class A Common Stock as a performance-related restricted stock unit award. This grant, which has no purchase price, will vest in 25% increments annually, increasing his direct ownership to 658,037 shares. The Form 4 filing confirmed this grant does not involve any share sales and is purely compensation.
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028
Ironwood Pharmaceuticals (NASDAQ: IRWD) has confirmed that the maturity date for its revolving credit facility remains December 31, 2028. This confirmation follows the company's notification to Wells Fargo Bank, National Association, the administrative agent, that it has satisfied the liquidity conditions as defined in its Credit Agreement. The 8-K filing indicates a moderate impact and neutral sentiment regarding this event.
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing
Ironwood Pharmaceuticals, Inc. filed a routine 8-K with the SEC announcing a reportable event dated March 10, 2026. The filing provides standard company details, confirms no amendments or material changes, and indicates no price-sensitive information. It serves primarily for regulatory compliance without impacting share value.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received an average "Hold" recommendation from eight brokerages, with an average one-year price target of $4.93. This comes despite a Q4 earnings miss and pipeline setbacks for apraglutide, which led to a share drop and revised 2026 guidance. However, significant institutional investors have increased their positions in the company, signaling continued interest despite recent challenges.
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue
Ironwood Pharmaceuticals (IRWD) closed FY 2025 with mixed Q4 results, showing a revenue decline but an improved net margin of 8.1%. While some see the firming margins and a significant valuation gap against DCF fair value as positive indicators for their GI and rare disease franchises, others highlight concerns over negative shareholders' equity, debt coverage by operating cash flow, and a non-recurring loss affecting profitability. The article suggests investors carefully evaluate these mixed signals to form their own view, particularly concerning the sustainability of the margin improvements amidst projected revenue declines and balance sheet pressures.
[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported the automatic sale of 32,582 shares across two transactions at weighted average prices of $3.81 and $3.66 per share. These sales were non-discretionary, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units. Following these sales, Shetzline beneficially owned 521,425 shares of Class A Common Stock.
Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding
Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, automatically sold 36,492 shares of Class A common stock to cover tax withholding obligations from vested restricted stock units. These non-discretionary transactions occurred on February 23 and 24, 2026, at weighted average prices of $3.81 and $3.66 per share. Following these sales, Minardo directly holds 363,886 Ironwood shares.
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Ironwood Pharmaceuticals reported its fourth quarter and full-year 2025 results, achieving its financial guidance for 2025 and reiterating a strong outlook for 2026. Key highlights include 11% LINZESS EUTRx demand growth in 2025, with revenue of $296 million and adjusted EBITDA of $138 million. The company expects 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion and adjusted EBITDA greater than $300 million, while advancing its apraglutide program with Phase 3 trial initiations expected in Q2 2026.
IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings
IRONWOOD PHARMACEUTICALS (IRWD) released its Q4 2025 earnings, reporting -$0.01 per share and $47.71 million in revenue, missing analyst estimates for both. The article also details recent insider trading, with two sales in the past six months, and hedge fund activity showing 116 institutional investors adding shares and 82 decreasing positions. Analysts have set a median price target of $6.5 for the stock.
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop
Ironwood Pharmaceuticals (IRWD) reported a significant miss on both Q4 2025 EPS and revenue forecasts, leading to a 16.62% drop in pre-market trading. Despite the setback, the company reiterated its 2026 guidance, expecting substantial sales growth for LINZESS and a significant reduction in debt. Ironwood plans to initiate a confirmatory Phase 3 clinical trial (STARS-2) for its drug apraglutide in Q2 2026, aiming for NDA submission by the end of 2029.
Ironwood Pharmaceuticals (NASDAQ: IRWD) proposes resale of RSU-derived shares
Ironwood Pharmaceuticals (NASDAQ: IRWD) has filed a Form 144, proposing the resale of Class A common stock that originated from restricted stock unit (RSU) awards. The filing details several RSU grant dates ranging from 2022 to 2025, with example share quantities, but does not provide specific timing for the sales or aggregate proceeds. This action indicates an intent to sell shares under Rule 144 procedures, subject to holding period and volume limitations.
